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Mycobacterium smegmatis is a fast-growing nonpathogenic species particularly useful in studying basic
cellular processes of relevance to pathogenic mycobacteria. This study focused on the D-alanine racemase gene
(alrA), which is involved in the synthesis of D-alanine, a basic component of peptidoglycan that forms the
backbone of the cell wall. M. smegmatis alrA null mutants were generated by homologous recombination using
a kanamycin resistance marker for insertional inactivation. Mutants were selected on Middlebrook medium
supplemented with 50 mM D-alanine and 20 g of kanamycin per ml. These mutants were also able to grow in
standard and minimal media without D-alanine, giving rise to colonies with a drier appearance and more-
raised borders than the wild-type strain. The viability of the mutants and independence of D-alanine for growth
indicate that inactivation of alrA does not impose an auxotrophic requirement for D-alanine, suggesting the
existence of a new pathway of D-alanine biosynthesis in M. smegmatis. Biochemical analysis demonstrated the
absence of any detectable D-alanine racemase activity in the mutant strains. In addition, the alrA mutants
displayed hypersusceptibility to the antimycobacterial agent D-cycloserine. The MIC of D-cycloserine for the
mutant strain was 2.56 g/ml, 30-fold less than that for the wild-type strain. Furthermore, this hypersuscep-
tibility was confirmed by the bactericidal action of D-cycloserine on broth cultures. The kinetic of killing for the
mutant strain followed the same pattern as that for the wild-type strain, but at a 30-fold-lower drug concen-
tration. This effect does not involve a change in the permeability of the cell wall by this drug and is consistent
with the identification of D-alanine racemase as a target of D-cycloserine. This outcome is of importance for the
design of novel antituberculosis drugs targeting peptidoglycan biosynthesis in mycobacteria.
Mycobacteria include the facultative intracellular pathogens
Mycobacterium tuberculosis and Mycobacterium avium. It has
been estimated that up to a third of the world’s population is
infected with M. tuberculosis (14). Microorganisms of the M.
avium complex have achieved prominence as major opportu-
nistic pathogens of AIDS patients. M. avium is naturally resis-
tant to most first-line antituberculosis drugs (19). This threat to
public health has been partially met by therapy with appropri-
ate antimicrobial agents, but unfortunately drug-resistant M.
avium and M. tuberculosis strains readily appear (6, 15), un-
derscoring the need to develop new and more effective anti-
mycobacterial agents.
Biosynthesis of the mycobacterial cell wall has received con-
siderable attention in the search for inhibitors useful for drug
therapy (7). These cell walls display a complex architecture of
glycolipids and proteins linked to the mycolyl-arabinogalactan-
peptidoglycan backbone (26). This structure is a barrier that
contributes to drug resistance (43), and many of its compo-
nents have been found to play a major role in pathogenesis
(11). The analysis of the M. tuberculosis genome sequence
suggests that peptidoglycan biosynthesis in mycobacteria fol-
lows the general pathway of other bacteria, including the for-
mation of the basic building block D-alanyl–D-alanine (2, 9, 44).
D-alanine racemase (Alr) catalyzes the conversion of L-alanine
into D-alanine (22), and D-alanine–D-alanine ligase catalyzes
the subsequent dimerization of D-alanine into the key dipep-
tide D-alanyl–D-alanine (27). The corresponding enzymes from
both Escherichia coli (23, 29) and mycobacteria (5, 13) are
inhibited by D-cycloserine (DCS), a D-alanine analog (28). The
dipeptide is then added to the UDP-tripeptide precursor by
the action of the D-alanine–D-alanine adding enzyme that com-
pletes the reactions of the D-alanine branch of peptidoglycan
assembly (45).
DCS is particularly effective against mycobacteria albeit with
marked side effects (10, 49). Moreover, overproduction of Alr
in Mycobacterium smegmatis, Mycobacterium intracellulare, and
Mycobacterium bovis BCG leads to a DCS-resistant phenotype.
We have also shown that the M. smegmatis enzyme is inhibited
by DCS in a concentration-dependent manner (5). Likewise,
the M. avium and M. tuberculosis enzymes produced from E.
coli recombinant clones are also inhibited by DCS (39). None-
theless, the specific characteristics of the mycobacterial en-
zymes involved in peptidoglycan biosynthesis, including the
essentiality of each of their functions, remain unknown. This
knowledge is important to the design of specific inhibitors that
would serve as novel bactericidal agents to treat M. tuberculosis
and M. avium infections. Furthermore, the inactivation of the
genes encoding for these enzymes may lead to the generation
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of attenuated strains of pathogenic mycobacteria that could
serve as candidate vaccines against tuberculosis.
M. smegmatis has been extensively used as a model system
for M. tuberculosis and other pathogenic mycobacteria. M.
smegmatis is nonpathogenic, requiring less stringent contain-
ment facilities, and it grows at a relatively high rate in a variety
of defined and nutrient-restricted media (20). M. smegmatis
has been used to study drug resistance mechanisms (5, 34, 41)
and basic physiological processes including the synthesis of
peptidoglycan precursors (8, 32). Insights gained from these
studies can then be applied to the pathogenic mycobacteria.
Thus, we started the genetic analysis of the D-alanine branch of
peptidoglycan biosynthesis in this model system and describe
the generation, isolation, and characterization of M. smegmatis
D-alanine racemase (alrA) mutants.
MATERIALS AND METHODS
Bacterial strains, plasmids, and culture conditions. Bacterial strains and plas-
mids used in this study are listed in Table 1. E. coli strains were grown at 37°C
in Luria-Bertani broth or agar. M. smegmatis strains were routinely grown at 37°C
in Middlebrook 7H9 base broth or agar (BBL Microbiology Systems, Cock-
eysville, Md.) supplemented with 0.5% bovine serum albumin fraction V (EM
Science, Gibbstown, N.J.), 0.01 M dextrose (Sigma Chemical Co., St. Louis,
Mo.), 0.015 M sodium chloride, and 0.2% glycerol (MADC). Broth medium was
also supplemented with 0.05% Tween 80 (Sigma), and solid medium was made
with 1.5% Bacto Agar (Difco Laboratories, Detroit, Mich.). When required,
D-alanine (Sigma) was used at 50 mM. Liquid cultures were incubated with
shaking at 200 rpm in an Innova 4300 rotary incubator (New Brunswick Scientific
Co. Inc., Edison, N.J.). As needed, the following antibiotics were used at the
specified concentrations: ampicillin (Sigma), 50 g/ml for E. coli; kanamycin A
monosulfate (Sigma), 25 g/ml for E. coli and 20 g/ml for M. smegmatis;
hygromycin B (Roche Molecular Biochemicals, Indianapolis, Ind.), 100 g/ml for
E. coli and M. smegmatis. For some experiments, M. smegmatis was grown in a
broth minimal medium based on the formulation of Zygmunt (50), as modified
by Ca´ceres (5a). Components and final concentrations were 5.0 mM ammonium
chloride, 6.8  107 mM calcium chloride, 8.4  107 mM cobalt(II) chloride,
22 mM dibasic potassium phosphate, 2.5  1010 mM ferric chloride, 21 mM
glycerol, 2.4 mM magnesium sulfate, 1.0  105 mM manganese chloride, 16
mM monobasic potassium phosphate, 4.9  106 mM pyridoxal hydrochloride,
0.4 mM Tween 80, and 8.6  106 mM zinc sulfate. Individual chemicals were
purchased from Sigma.
Bacterial transformation. E. coli was transformed as previously described (1).
For the generation of M. smegmatis alrA mutants, 50 ml of an early exponential
phase culture of M. smegmatis mc2155 was washed twice and concentrated
100-fold in cold 10% ultrapure glycerol (Invitrogen Life Technologies, Carlsbad,
Calif.). Concentrated cells were electroporated with approximately 5.0 g of the
BamHI-KpnI fragment of pTAMU2 carrying the inactivated alrA gene. Electro-
poration was carried out at 2,500 V, 100 F, and 246  in an electrocell
manipulator (model 600; BTX Inc., San Diego, Calif.). Electroporated cells were
allowed to recover at 37°C in MADC broth and plated on MADC agar supple-
mented with 50 mM D-alanine (Sigma) and kanamycin (20 g/ml; Sigma). For
the genetic complementation experiment, 50 ml of an early-exponential -phase
culture of M. smegmatis TAM23 alrA mutant was electroporated with 1.5 mg of
pTAMU3 DNA at 2,500 V, 25 F, and 1,000  in a Gene Pulser electrocell
manipulator (Bio-Rad Laboratories, Richmond, Calif.), as previously described
(16). Transformants were selected on MADC agar supplemented with hygromy-
cin (100 g/ml; Roche).
Nucleic acid manipulations. Mycobacterial DNA was isolated by the standard
method using cetyl trimethyl ammonium bromide (1). Plasmid DNA was isolated
by an alkaline lysis method as previously described (36), using a large-scale
isolation kit (Promega, Madison, Wis.) as recommended by the manufacturer.
DNA fragments used for plasmid construction in E. coli and for recombination
experiments in M. smegmatis were purified by gel electrophoresis and recovered
by absorption to glass particles (GeneClean Bio 101, Vista, Calif.) as recom-
mended by the manufacturer. Standard procedures were followed for restriction
digestions, ligations, and agarose gel electrophoreses (36).
Amplification of the alrA gene was carried out with 50 ng of M. smegmatis
genomic DNA template using primers NAN-1 (5-TCTGCGGCCTCTGGGAC
AATGGG-3) and NAN-2 (5-GACACACCTGCCACGGTGCCGAC-3) for
27 cycles in a thermal cycler (Perkin-Elmer Gene Amp PCR System 2400; Roche
Molecular Systems, Branchburg, N.J.) as previously described (5). For Southern
blotting analysis, approximately 3.0 g of M. smegmatis genomic DNA was
digested with SmaI, and DNA fragments were separated on a 0.8% agarose gel,
subjected to an alkaline denaturing procedure, and transferred to Biotrans nylon
membranes (ICN Biomedicals, Inc., Costa Mesa, Calif.). Membranes were hy-
bridized with a probe corresponding to the 1.9-kb BamHI/PvuII fragment con-
taining the wild-type M. smegmatis alr gene, which was radiolabeled with
[-32P]dCTP using the Rediprime DNA labeling II system (Amersham Pharma-
cia Biotech, Inc., Piscataway, N.J.) as recommended by the manufacturer. Pre-
hybridization and hybridization were performed at 56°C. Washes were done
under high-stringency conditions at 65°C as previously described (36).
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s) Source or reference
Strains
E. coli DH5a F lacZDM15 endA1 hsdR17 supE44 gyrA96 relA1 Invitrogen Life
Technologies
E. coli XL2-Blue MRF D(mcrA)183 D(mcrCB-hsdSMR-mrr) 173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac
[F proAB laclqZDM15 Tn10 Tetr Camr]
Stratagene
M. smegmatis mc2155 Alr; high-efficiency plasmid transformation mutant of M. smegmatis mc26 37
M. smegmatis TAM20 Alr Kanr; M. smegmatis alr mutant derived from mc2155 This study
M. smegmatis TAM23 Alr Kanr; M. smegmatis alr mutant derived from mc2155 This study
M. smegmatis TAM23
(pTAMU3)
Alr Hygr Kanr; M. smegmatis alr mutant complemented with wild-type gene
integrated at the mycobacteriophage L5 attB site
This study
Plasmids
pBUN82 Kanr; recombinant plasmid carrying the alr gene from M. smegmatis mc2155 in
a 1.9-kb BamHI/PvuII fragment
5
pBluescript II KS  Ampr; standard E. coli cloning vector Stratagene
pTAMU1 Ampr; pBluescript II KS() with the 1.9-kb BamHI/PvuII fragment of pBUN82 in
the BamHI/EcoRV site
This study
pTAMU2 Ampr Kanr; pTAMU1 with the 1.24-kb PstI aph fragment of pUC4K (Pharmacia)
in the PstI site
This study
pTAMU3 Ampr Hygr; pYUB412 with the 1.9-kb BamHI/PvuII fragment of pBUN82 in the
BclI/EcoRV site
This study
pYUB412 Ampr Hygr; E. coli-Mycobacterium integration-proficient vector; integrates at the
mycobacteriophage L5 attB site
33
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Gram staining and acid-alcohol resistance testing. M. smegmatis cells were
stained by the crystal violet method using a Gram stain kit (Sigma) as recom-
mended by the manufacturer. Acid-alcohol resistance was determined by the
Ziehl-Neelsen acid-fast procedure using the TB Stain Kit ZN (Difco), as rec-
ommended by the manufacturer.
Electron microscopy. Strains were grown to an optical density at 600 nm
(OD600) of approximately 1.0 in MADC-Tween, with or without D-alanine. Cells
were harvested, washed twice with phosphate-buffered saline (PBS)–0.05%
Tween, and fixed for 1 h in 2.5% buffered glutaraldehyde, washed twice, and
postfixed with 2.0% osmium tetroxide. After repeated washings in PBS, samples
were dehydrated in a graded series of ethanol solutions, washed twice in pro-
pylene oxide, and embedded with Araldite resin. Thin sections were examined
with a Philips 201 transmission electron microscope (Philips Electron Optics,
Eindhoven, The Netherlands) at an accelerating voltage of 60 kV.
D-Alanine racemase assays. Approximately 200-ml cultures of M. smegmatis
mc2155 or TAM23 were grown in MADC-Tween with or without D-alanine until
they reached an OD600 of ca. 1.0. Cultures were washed twice and concentrated
50-fold in 50 mM Tris-HCl (pH 8.0). Cells were sonicated on a salt-ice-water
bath with a Vibra-Cell model VC600 sonicator (Sonic and Materials, Inc., Dan-
bury, Conn.). Sonication was carried out for 2 min at 80% power output and 50%
duty cycle, and in the presence of 30% (vol/vol) type A-5 alumina (Sigma). The
resulting active cell extracts were centrifuged at 4°C in a JA-17 rotor (Beckman
Instruments, Inc., Fullerton, Calif.) for 30 min at 15,000 rpm, dialyzed against 50
mM Tris-HCl (pH 8.0), and sterilized by filtration through a 0.22-m-pore-size
filter (Advantec MFS Inc., Pleasanton, Calif.). Protein concentration was deter-
mined by the DC assay (Bio-Rad) as recommended by the manufacturer. Alr
activity in the active cell extracts was assayed in the direction of the conversion
of L-alanine into D-alanine by a modification of the coupled-spectrophotometric
method previously described (5, 48). To start the reactions, active crude cell
extracts were added to 1.0 ml of prewarmed mixtures containing 50 mM Tris-HCl
(pH 8.0), 0.1 mM pyridoxal phosphate (Sigma), and 15 mM L-alanine (Sigma).
After 15 min of incubation at 37°C, when the conversion of substrate into
product remains linear, reactions were stopped by boiling for 10 min. Subse-
quently, 1 U of D-amino acid oxidase (Calzyme, San Luis Obispo, Calif.), 0.2 mM
NADH (Roche Laboratories), and 10 U of rabbit muscle lactic dehydrogenase
(Sigma) were added. The coupled reaction was measured by the change in
absorbance at 340 nm after 5 h of incubation at 37°C. All samples were measured
in triplicate. Specific activities (in micromoles of consumed substrate minute1
milligram1) were calculated as previously described (5).
LDH assays. L-Lactate dehydrogenase (LDH) activity endogenous to crude
cell extracts of M. smegmatis was measured in the direction of the conversion of
pyruvate into lactate coupled to the oxidation of NADH as previously described
in the Worthington enzyme manual (Worthington Biochemical Corp., Lake-
wood, N.J.). Crude cell extracts were added to 1.0 ml of prewarmed mixtures
containing 50 mM Tris-HCl (pH 8.0), 1.0 mM sodium pyruvate (Sigma), and 0.2
mM NADH (Roche). The change in absorbance at 340 nm was measured after
1 h of incubation at 37°C. All samples were measured in triplicate. Specific
activities (in micromoles of consumed substrate minute1 milligram1) were
calculated as described in the enzyme manual mentioned above by subtracting
the background change in absorbance (obtained from boiled inactivated extracts
processed in identical manner) from the change in absorbance obtained with the
active cell extracts.
Drug susceptibility assays. MICs were determined by a microplate twofold
dilution method, as described by Takiff et al. (40), with modifications. M. smeg-
matis mc2155 and TAM23 cells were grown in 25 ml of MADC-Tween with and
without 50 mM D-alanine to an OD600 of approximately 1.0. Bacteria were
washed with PBS-Tween, and 105 CFU was inoculated onto each well containing
serial twofold dilutions of various antimicrobial agents. Plates were incubated at
37°C, and visual inspection to determine MICs was carried out at 48 h. The MIC
is defined as the lowest concentration that prevents observable bacterial growth
and is determined by the consistent result of three independent cultures, each
assayed in triplicate.
Bactericidal action of DCS. M. smegmatis strains mc2155 and TAM23 were
grown in MADC-Tween broth at 37°C to an OD600 of ca. 0.5. These starter
cultures were used to inoculate 200 ml of MADC broth, and cells were then
grown to an OD600 of ca. 0.4. Two 50-ml aliquots of these exponentially growing
cultures were transferred to separate flasks. DCS was added to one of the
corresponding cultures, with the other serving as a growth control. Concentra-
tions of DCS were 50 times the MIC for each strain (3.75 mg/ml for mc2155 and
128 g/ml for TAM23). All cultures were incubated at 37°C in a shaking incu-
bator for 72 h. The OD600 was measured for each culture at 3, 6, 9, 12, 24, 48, and
72 h. Concurrently, aliquots were taken, serially diluted, and plated onto MADC
agar in triplicate to determine numbers of viable bacterial counts.
Uptake assays. For D-alanine uptake assays, we used a modification of the
method described by David (12). Cells exponentially growing in MADC-Tween
(OD600, ca. 1.0) were collected by centrifugation at 4°C, washed once in ice-cold
50 mM Tris-HCl buffer (pH 8.0) containing 0.05% Tween 80, and concentrated
20 times in the same buffer. Samples were prewarmed for 10 min at 37°C, and
D-alanine was added to a final specific activity of 3.0 Ci of [14C]-1-D-alanine
(ICN) per mol and 0.2 mM concentration. Samples were placed in a 37°C water
bath. Aliquots were taken at various times and immediately placed on ice. The
sample for each time point was divided in three subsample triplicates of 0.5 ml
and filtered through 0.8-m-pore-size membrane filters (Millipore Corp., Bed-
ford, Mass.) in a manifold. Each filter was washed three times with 10 ml of cold
buffer, dried under a heat lamp, and weighed. The cell-associated radioactivity
was determined in a liquid scintillation counter (Wallac 1410; Pharmacia, Pis-
cataway, N.J.) using EcoLite scintillation cocktail (ICN). Uptake data were
expressed as micromoles of D-alanine per milligram (dry cell weight).
Since radiolabeled DCS is not commercially available, an uptake assay was
developed based on the colorimetric determination of this compound (21). Cells
exponentially growing in MADC-Tween (OD600 of 1.0) were harvested at 4°C
by centrifugation, washed twice with water, and concentrated 40 times. Samples
were prewarmed at 37°C for 10 min, and DCS was added to a final concentration
of 250 g/ml (2.5 mM). Cells were placed in a 37°C water bath. Aliquots were
taken at various times and immediately placed on ice. After 20 min of incubation,
clumping of TAM23 cells was evident and uptake determinations became unre-
liable. Each time point sample was washed twice with water, resuspended, and
sonicated. Protein concentration was determined using the Bio-Rad DC assay,
followed by protein removal through serial passages of both YM-10 and YM-3
Centricon concentrators (Millipore Corp.). The concentration of DCS was de-
termined by measuring the OD620 after adding a specific color-developing re-
agent as previously described (21). A standard curve was generated by diluting a
DCS standard in a cell extract that was prepared from cells not exposed to DCS.
Uptake data were expressed as micromoles of DCS per milligram of protein.
Since D-alanine and DCS uptake assays do not measure the same parameters,
reported values for each assay cannot be directly compared.
RESULTS
Inactivation of the M. smegmatis alrA gene. To inactivate the
alrA gene in M. smegmatis, a DNA fragment carrying the wild-
type gene was subcloned into the E. coli cloning vector pBlue-
script II KS() to yield the recombinant plasmid pTAMU1
(Table 1). Then, the 1.2-kb kanamycin resistance determinant
from plasmid pUC4K containing the aminoglycoside 3-phos-
photransferase type I-coding gene from transposon Tn903 (30)
was inserted at the unique PstI site internal to the alrA gene.
The resulting construct, pTAMU2, carries an insertionally in-
activated alrA gene, which can be excised as a linear 3.2-kb
BamHI-KpnI fragment (Table 1). Based on the hypotheses
that D-alanine is an essential component and that AlrA is the
only enzyme responsible for D-alanine biosynthesis in M. smeg-
matis, it was predicted that an alrA mutant would be dependent
on D-alanine for growth. Thus, the step to select for this mutant
was carried out in MADC agar supplemented with 50 mM
D-alanine in addition to 20 g of kanamycin per ml. Transfor-
mation of M. smegmatis mc2155 with the 3.2-kb linear fragment
carrying the inactivated alrA gene yielded 25 kanamycin-resis-
tant transformants, and 2 of these, designated TAM20 and
TAM23, were further analyzed.
To determine whether these transformants carry an inacti-
vated alrA gene, genomic DNA was isolated and amplified by
PCR. As expected for the inactivation of the alrA gene,
genomic DNA from both TAM20 and TAM23 yielded the
2.4-kb product. Southern blotting analysis was used to verify
the occurrence of these recombinational events in the appro-
priate M. smegmatis strains (data not shown). Genomic DNA
was isolated; digested with SmaI, which cuts once within the
alrA gene; transferred to a membrane; and hybridized with the
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wild-type alrA gene fragment as a probe. The wild-type strain
mc2155 gave two homologous bands of approximately 15.0 and
1.8 kb, whereas TAM20 and TAM23 yielded a mutant-type
pattern with three bands of approximately 15.0, 2.2, and 1.2 kb.
These patterns were as expected for the predicted recombina-
tional events, validating the construction of the strains de-
scribed herein.
Phenotypic characterization of M. smegmatis alrA mutants:
independence of D-alanine for growth. The identification of
only one D-alanine racemase gene in the mycobacterial ge-
nome sequencing projects suggests that M. smegmatis alrA mu-
tants may be dependent on exogenous D-alanine for growth.
Both mutant strains, TAM20 and TAM23, exhibited wild-type
growth in MADC agar supplemented with D-alanine, giving
rise to typical flat-border colonies after 3 days of incubation at
37°C. In the absence of D-alanine, TAM20 and TAM23 cells
were also able to grow, but colonies displayed a drier appear-
ance with more-raised borders. Complementation of TAM23
with the integrating construct pTAMU3 introduces a wild-type
alrA gene at the mycobacteriophage L5 attachment site (24,
31) and fully restores wild-type colony morphology. Except for
these differences in colony morphology, no other observable
differences were detected by light or electron microscopy when
cells were grown in the presence or absence of D-alanine.
Bacilli from both wild-type and mutant strains were weakly
gram positive, acid fast, and displayed the same aspect of
elongated rods. Likewise, at the ultrastructural level, cells did
not differ in either shape, size, or thickness of the cell walls. In
summary, M. smegmatis alrA mutants are independent on ex-
ogenous D-alanine, a property that was further confirmed by
their ability to grow in MADC (see below and Fig. 2) and
minimal broth containing mineral salts, glycerol, pyridoxal
phosphate, and Tween 80 (data not shown).
M. smegmatis alrA mutants have no detectable D-alanine
racemase activity. To determine whether M. smegmatis alrA
mutants are or are not devoid of Alr activity, crude cell extracts
from wild-type and mutant strains were prepared and assayed
for enzyme activity (Fig. 1). Protein extracts prepared from
wild type mc2155 cells grown in the presence or absence of
D-alanine displayed approximately equal levels of Alr activity
that matched the specific activities previously reported (5). In
contrast, extracts from TAM23 prepared from cells grown in
the presence or absence of D-alanine lacked any detectable Alr
activity. These extracts yielded background levels of Alr activ-
ity not significantly different from the levels obtained by re-
placing bovine serum albumin for TAM23 extracts in the re-
action mixture. This absence of Alr activity in TAM23 extracts
was not due to the presence of an inhibitor since mixtures of
TAM23 and mc2155 extracts gave the Alr activity proportional
to the amount of enzyme present in the active extract from the
wild-type strain. Furthermore, to rule out the possibility that
sonic disruption may have damaged more readily protein ex-
tracts of potentially fragile TAM23 cells, LDH activity was also
measured. The M. smegmatis LDH activity was found to be
more sensitive to prolonged sonic disruption (data not shown)
and provides a useful control to determine whether TAM23
extracts are enzymatically active. In contrast to the results
obtained in the Alr assay, extracts from both mc2155 and
TAM23 displayed similar levels of LDH activity above back-
ground levels. Furthermore, complementation of TAM23 with
a wild-type alr gene restored Alr activity. Thus, it was con-
cluded that inactivation of the alrA gene results in no detect-
able Alr activity in the M. smegmatis alrA mutant strain.
M. smegmatis alrA mutants are hypersusceptible to D-cy-
closerine. The inhibition of AlrA by DCS in a concentration-
dependent manner indicates that this enzyme serves as one of
the drug targets (5). However, the dispensability of the alrA
gene for growth in vitro suggests that it is not the main target
responsible for the bactericidal effect of DCS. Since overpro-
duction of the enzyme leads to increased resistance to DCS, it
appears that binding of DCS to AlrA protects another target
within the cell. This hypothesis predicts that alrA null mutants
would be hypersusceptible to DCS. Thus, the corresponding
MICs for wild-type and TAM23 alrA mutant strains were de-
termined.
For MIC tests, M. smegmatis cells grown with and without
FIG. 1. Specific activities of D-alanine racemase and LDH in M.
smegmatis cell extracts. Mean specific activities (in micromoles) of
substrate consumed minute1 milligram1, of D-alanine racemase (sol-
id bars) and LDH (striped bars) from wild-type and mutant strains
were determined in cell extracts prepared as described in Materials
and Methods. Cells were grown to exponential phase in medium with
or without D-alanine (50 mM) as indicated at the bottom of the figure.
Extracts were prepared from three independent cultures for each
strain and medium and assayed in triplicate. Combined extracts of
mc2155 and TAM23 (ca. 1:24 [wt/wt] protein mixture ratio, with
TAM23 extract as the predominant component) were also assayed in
triplicate. A mock assay was also carried out with bovine serum albu-
min (BSA) in place of equivalent amounts of the corresponding cell
extracts. N.D., not determined. Error bars, standard deviations.
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D-alanine were inoculated onto complete Middlebrook MADC
broth without D-alanine. The MIC of DCS for the wild-type
strain was 75 g/ml, independent of the presence of D-alanine
in the original inoculum (Table 2). As expected, TAM23 was
about 30-fold more sensitive (MIC, 2.56 g/ml) when the in-
oculum was grown without D-alanine. Since TAM23 cells carry
a mutation in a gene responsible for D-alanine biosynthesis, it
is possible that growth in the presence of D-alanine partially
restores wild-type MICs of DCS. To test this hypothesis,
TAM23 was grown with D-alanine, harvested, washed exten-
sively to prevent D-alanine carryover, and inoculated into the
MIC test cultures. These conditions resulted in a fourfold
increase in the MIC (MIC, 10.2), still about 7.5 times lower
than the MIC for the wild-type strain. As a control, the MICs
of the unrelated drugs amikacin, ethambutol, and rifabutin
were also determined. The MICs for both wild-type and mu-
tant strains were the same, independently of the presence or
absence of D-alanine in the medium used to grow the inocula
to determine the MICs. The effect of the addition of D-alanine
directly into the MIC test cultures was also determined. D-
Alanine would be expected to effectively compete with DCS
and decrease the susceptibilities of both strains to DCS. As
expected, under these conditions, the MIC of DCS for both
wild-type and TAM23 strains increased dramatically to 1,200
g/ml independently of prior growth conditions of the inocula.
No significant differences were observed for the other unre-
lated drugs, demonstrating that the effect was specific for DCS.
Complementation of strain TAM23 with the integrating vector
pTAMU3, which carries the wild-type alr gene, resulted in a
strain for which the MICs were identical to those for the wild
type (data not shown).
This hypersusceptibility indicated by the MIC growth inhi-
bition data was also confirmed by the analysis of the bacteri-
cidal action of DCS in broth cultures grown in absence of
D-alanine. Pilot experiments were performed with each strain
to determine the optimal DCS concentration that resulted in a
strong bactericidal effect. In the final experiment, cultures were
grown to an early exponential phase (OD600 of 0.4), split in
two, and DCS was added to one of these subcultures at 50
times the MIC. In absence of DCS, both the wild-type strain
mc2155 and the TAM23 mutant cells grew to an OD600 of	2.0
(Fig. 2A) and reached saturation at a cell density approxi-
mately above 5.0  108 (Fig. 2B). These data also confirmed
the independence of M. smegmatis alr mutants on D-alanine for
growth and further demonstrate that alr mutants can grow in
absence of D-alanine at approximately the same growth rate as
wild-type cells. In contrast, in the presence of DCS both cells
underwent rapid death by lysis as revealed by both the drastic
decrease observed in optical density and viable counts. Fur-
thermore, the kinetic of killing was similar for both the wild-
type and mutant strains. However, it must be emphasized that
considering absolute drug concentrations, the effect on the
mutant strain is observed at a 30-fold-lower concentration than
for the wild-type strain. This pattern suggests that the bacteri-
cidal action of DCS is due to the inhibition of a more funda-
mental target different from AlrA.
FIG. 2. Bactericidal action of DCS on M. smegmatis wild-type and
alr mutant strains. Cells were grown in MADC broth without D-alanine
to an OD600 of ca. 0.4. At this time (time zero), cultures for each strain
were split in two, and DCS was added to one of these subcultures at a
concentration of 50 times the MIC for the corresponding strain (see
Materials and Methods). ODs (A) and CFU per milliliter (means 

standard deviations [error bars] of triplicate measurements) (B) were
determined for mc2155 in the subcultures with (open circles) or with-
out (closed circles) DCS. Identical measurements were performed for
the corresponding subcultures of TAM23 with (open squares) or with-
out (closed squares) DCS.
TABLE 2. Determination of MICs of selected antimycobacterial
agents for M. smegmatis strains determined with
inocula grown with or without D-alanine
Drug
MICa (g/ml) of drug for strain grown as indicated
Wild-type mc2155 TAM23 alr mutant
Without
D-alanineb
With
D-alaninec
Without
D-alanineb
With
D-alaninec
Amikacin 1.56 NDd 1.56 1.56
DCS 75.0 75.0 2.56 10.2
Ethambutol 3.13 ND 3.13 3.13
Rifabutin 2.00 ND 2.00 1.00
a MICs were determined in complete Middlebrook 7H9 medium as described
in Materials and Methods. For a given drug, MIC differences between the two
strains are considered significant when values correspond to a separation of at
least 2 doubling dilutions.
b Inoculum was grown in complete Middlebrook 7H9 medium without D-
alanine supplementation, as described in Materials and Methods.
c Inoculum was grown in complete Middlebrook 7H9 medium supplemented
with 50 mM D-alanine, as described in Materials and Methods.
d ND, not determined.
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An alternative explanation for the increased susceptibility of
the null mutants to DCS is that the inactivation of the alrA
gene changes the permeability of the cell wall to DCS. This
alteration may not be detectable by morphological studies. To
test this hypothesis, we developed a methodology to perform
DCS uptake assays. The results obtained were similar for both
wild-type and mutant strains (Fig. 3A). We also carried out
D-alanine uptake assays using a standardized procedure ob-
taining similar results for both strains (Fig. 3B). Thus, it is not
likely that a permeability change is responsible for the ob-
served phenotype of the null mutants.
DISCUSSION
In this study, it was shown that the M. smegmatis alrA gene
can be insertionally inactivated to generate null mutants. PCR
and Southern blotting analyses of wild-type and mutant strains
confirmed the inactivation of the alrA gene in TAM20 and
TAM23 by gene replacement via a double-crossover event
between the M. smegmatis chromosome and the linear frag-
ment carrying the inactivated gene. Thus, alrA mutants are
viable and can grow in medium without D-alanine. Comple-
mentation of the alrA mutant strain with a wild-type alrA copy
restores the wild-type phenotype, indicating that properties of
the mutant strain are due to the inactivation of the alrA gene
rather than a polar effect on the expression of a downstream
gene. The independence of M. smegmatis alrA mutants of D-
alanine for growth indicates that this mutation does not impose
an auxotrophic requirement for D-alanine. This phenotype has
significant implications for the synthesis of D-alanine and pep-
tidoglycan in M. smegmatis and possibly other mycobacterial
species.
D-Alanine is an essential component for bacteria with a
peptidoglycan layer structure. The essentiality of D-alanine
stems from the key role of the dipeptide D-alanyl–D-alanine in
the cross-linking of peptidoglycan strands (38). The repeating
unit of the peptidoglycan from M. smegmatis has a D-alanine
moiety (35), and D-alanyl–D-alanine is the only product de-
tected in a biochemical assay using partially purified extracts of
M. smegmatis D-alanine ligase (34). These properties support
the hypothesis that D-alanine is also an essential component
for M. smegmatis. In the context of this hypothesis, the inde-
pendence of alrA mutants of D-alanine for growth suggests that
M. smegmatis may have alternative pathways for the biosynthe-
sis of D-alanine. Listeria monocytogenes, for example, has been
shown to possess such metabolic routes (42).
Our studies are consistent with the existence of one D-ala-
nine racemase in M. smegmatis, in contrast to the two alanine
racemases identified in E. coli (4, 25) and Salmonella enterica
serovar Typhimurium (17, 46, 47). Our Alr assay, as shown by
the mixing of active and inactive extracts, was capable of de-
tecting specific activities in the range of 0.002 mol mg1
min1, corresponding to about 4% of the maximal activity
obtained with extracts of the wild-type strain. Thus, although
our data cannot completely rule out the presence of a second
low-level Alr activity, this possibility is not likely. The indepen-
dence of M. smegmatis alrA mutants from D-alanine for growth
differs from the absolute dependency of Lactobacillus planta-
rum alr mutants (18). This is consistent with the existence of
only one pathway for D-alanine biosynthesis in L. plantarum
catalyzed by its sole D-alanine racemase, encoded by a single
copy of the gene. The likely existence of a second pathway of
D-alanine biosynthesis in M. smegmatis would leave unresolved
whether endogenous D-alanine biosynthesis is or is not an
essential function. In contrast, endogenous biosynthesis of dia-
minopimelate was shown to be an essential function of M.
smegmatis since ask single mutants, auxotrophic for diamin-
opimelate, could not be obtained even in medium supple-
mented with this nutrient (32). It remains to be tested if the
inactivation of the gene(s) responsible for a putative second
pathway of D-alanine biosynthesis in an alrA background
would render viable mutants.
The uptakes of D-alanine and DCS in both wild-type and
mutant strains were not significantly different, indicating that
changes in cell wall permeability are not a likely explanation
for the DCS hypersusceptible phenotype of the alr mutant
strain (Fig. 3). Thus, the hypersusceptibility of TAM23 cells to
DCS is consistent with the existence of multiple targets for
DCS. Our previous studies identified D-alanine racemase as
one of these targets (5). The lack of the racemase protein in
the alrA mutant strain may lead to a hypersusceptible pheno-
type since more DCS would be required to inhibit both the
racemase and an additional target(s) in the wild-type strain. In
contrast, the bactericidal effect of DCS suggests the existence
FIG. 3. Uptake of D-alanine and DCS by M. smegmatis wild-type
and alr mutant strains. Uptake assays for DCS (A) or D-alanine (B) for
strains mc2155 (closed circles) and TAM23 (open circles) were carried
out in as described in Materials and Methods. Values are means 

standard deviations (error bars) of triplicate measurements.
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of another lethal target. In this context, D-alanine ligase is an
attractive candidate since this enzyme activity is also inhibited
by DCS (13). More importantly, the construction of a condi-
tionally lethal mutant bank led to the isolation of a thermo-
sensitive mutant impaired in this gene function (3). Further-
more, DCS hypersusceptibility may reflect an alteration of the
peptidoglycan structure of TAM23 cells, as a direct conse-
quence of the inactivation of the alr gene. In this context,
TAM23 cells were also more susceptible to DCS than were
wild-type cells when grown in medium with D-alanine, but
mutant cells grown without D-alanine became hypersusceptible
to both growth inhibition and the bactericidal action of DCS
(Table 3; Fig. 2).
In summary, the D-alanine independent phenotype of M.
smegmatis alrA mutants suggests that M. smegmatis has another
pathway of D-alanine biosynthesis. Given the conservation of
basic physiological processes, this finding could also be of sig-
nificance for pathogenic mycobacteria and the design of atten-
uated strains and antimycobacterial agents.
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